Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS )

20.35 +0.63 (+3.19%)
Streaming Delayed Price Updated: 11:48 AM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 Next >
GeneDx to Participate in Upcoming Investor Conferences
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in 44th Annual Cowen Health Care Conference
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Preliminary 2023 Financial Results
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene... 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Evolution of Executive Leadership Team
Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership... 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms 
From GeneDx Holdings Corp.; PacBio
Via GlobeNewswire
GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients
Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in Upcoming Investor Conferences in June
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
From GeneDx Holdings Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.